Tagged with Reimbursement

Sweden Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. Mattias Bankel, Head of Nordics and Baltics, shares his journey of establishing and developing Amicus’s presence in Sweden and other Nordic countries, furthermore his commitment to ensure that…

China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

Opinion Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring a more comprehensive rollout of these models around the globe.   We’re looking forward to being one customer of many…

Italy Managing partner of the law firm Herbert Smith Freehills in Italy, Laura Orlando is one of Italy’s leading life sciences specialists, with a focus on IP and regulatory matters.  Together with Sara Balice, one of the firm’s senior associates they examine the Court of Justice of the European Union’s (CJEU) ruling on…

Turkey In Summer 2018, we spoke to Adriano Antonio Treve, then general manager of Roche Turkey, now Area Head Central Eastern Europe, Turkey, Russia, Central Asia, Iran, Pakistan & Indian Subcontinent. Treve provided insights into the main opportunities and challenges of the Turkish market, Roche’s unrivalled commitment to making a difference…

Baltics Andrejs Pantelejevs, head of bureau of the Ministry of Health of Latvia, discusses the importance of channeling the recent EUR 200 million healthcare financing to raising the wages of practitioners, reimbursing expensive innovative medicines in therapeutic areas such as oncology and cardiovascular diseases as well as strengthening e-health. Can you…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…

Canada Imran Ali, senior manager of the pan-Canadian Pharmaceutical Alliance (pCPA) Office, the body that provides dedicated centralized support to the national negotiating process for drug prices, representing all 14 public drug plan jurisdictions in Canada, discusses the mandate of the pCPA, the main achievements so far, as well as the…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

Poland Wojciech Koziejowski, managing director of Lundbeck Poland, discusses attaining reimbursement in Poland for the first time in ten years and the recent set-up of their global shared service center of more than 200 staff in Krakow. Moreover, he highlights the leading role the company is taking in educating key stakeholders…

Poland Irena Rej, president of the Polish Pharmaceutical Chamber, Farmacja Polska, discusses the trends of the domestic pharmaceutical market and the recent changes to improve the introduction of innovative products. Furthermore, she highlights the strengths of the local OTC industry and the chamber’s role in facilitating active dialogue with key stakeholders…